Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2384484 | 1.00 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL12254528 | 0.88 | L3MBTL1 (0.49) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2384054 | 0.88 | L3MBTL1 (0.52) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2384050 | 0.88 | L3MBTL1 (0.52) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2383516 | 0.88 | HDAC4 (0.53) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2385869 | 0.88 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2384782 | 0.88 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2385866 | 0.88 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2384785 | 0.88 | L3MBTL1 (0.47) | L3MBTL1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2383515 | 0.88 | HDAC4 (0.53) | L3MBTL1MEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1960363-B1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, COMPOSITIONS AND USES THEREOF | AMGEN INC (US) | 2014-01-22 | — | — | EP | claimed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8017626-B2 | Quinolone based compounds exhibiting, prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-13 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-8012968-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | AMGEN INC. | 2010-07-22 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-7728130-B2 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity | AMGEN INC. (US) | 2010-06-01 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | AMGEN INC. | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184763-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING, PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | L3MBTL1 4035/4885MEN1 3474/4885KMT2A 942/4885 |
| US-20100240610-A1 | QUINOLONE BASED COMPOUNDS EXHIBITING PROLYL HYDROXYLASE INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF | EGLN3, HIF1AN, EGLN2 | L3MBTL1 4024/4885MEN1 3364/4885KMT2A 833/4885 |
| US-20070249605-A1 | Quinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions, and uses thereof | EGLN3, HIF1AN, EGLN2 | L3MBTL1 4024/4885MEN1 3364/4885KMT2A 833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.